Find a Doctor
Mihaela Druta, MD
Specialty: Medical Oncology
Program: Sarcoma
Call 1-888-MOFFITT
(1-888-663-3488)
Call 1-888-MOFFITT
(1-888-663-3488)
Locations: Moffitt Cancer Center
Cancer Focus: GIST (Gastrointestinal Stromal Tumor) , Osteosarcoma , Sarcoma
Dr. Druta earned her MD degree from the University of Medicine and Pharmacy Carol Davila, Romainia. She completed an Internal Medicine Residency and Hematology/Medical Oncology Fellowship at the University of South Florida at Moffitt Cancer Center. Dr. Druta most recently completed a Sarcoma Medical Oncology Fellowship (Willie Tichenor Sarcoma Fellowship) at MD Anderson Cancer Center. Dr. Druta's clinical interest is in the development of clinical trials focusing on targeted therapeutics specific to sarcoma patients. Her research interest is in the translational aspects of sarcoma biology focusing specifically on Well-differentiated/Differential Liposarcoma and Leiomyosarcoma.
Education & Training
Board Certification:
- Internal Medicine
- Internal Medicine
Fellowship:
- H. Lee Moffitt Cancer Center - Hematology and Medical Oncology
- MD Anderson Cancer Center - Sarcoma Medical Oncology
Residency:
- University of South Florida - Internal Medicine
Medical School:
- University of Medicine and Pharmacy Carol Davilla - MD
CLINICAL TRIAL 18431
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention:
Open
CLINICAL TRIAL 19504
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Condition: Sarcoma
Intervention: Avapritinib (); BAY 73-4506 (Regorafenib); BLU-285 (Avapritinib); Not Applicable (); Regorafenib (Stivarga)
Open
CLINICAL TRIAL 19707
Phase 1 Dose Escalation, Multi-Tumor Study To Assess The Safety, Tolerability And Antitumor Activity Of Genetically Engineered Mage-A4c1032t In Hla-A2+ Subjects With Mage-A4 Positive Tumors
Condition: Sarcoma
Intervention: MAGE-A4 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open
CLINICAL TRIAL 19487
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Condition: Sarcoma
Intervention: BMS-936558 (Nivolumab); Nivolumab (); azacitidine (5-azacitidine)
Open
CLINICAL TRIAL 18782
A Pilot Study Of NY-ESO-1c259T Cells In Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Condition: Sarcoma
Intervention: NY-ESO-1c259T (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open
CLINICAL TRIAL 19776
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients
with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3021 ()
Open
CLINICAL TRIAL 19414
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Talimogene Laherparepvec (OncoVEX); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec)
Open
CLINICAL TRIAL 20309
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Condition: Sarcoma
Intervention: DCC-2618 (); Sunitinib Malate (SU011248)
Open
If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.
- Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 Oct.7(1):276. Pubmedid: 31651363. Pmcid: PMC6813983.
- Bridge JA, Sumegi J, Druta M, Bui MM, Henderson-Jackson E, Linos K, Baker M, Walko CM, Millis S, Brohl AS. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019 Jun.32(11):1593-1604. Pubmedid: 31189996.
- Pham V, Henderson-Jackson E, Doepker MP, Caracciolo JT, Gonzalez RJ, Druta M, Ding Y, Bui MM. Practical Issues for Retroperitoneal Sarcoma. Cancer Control. 2016 Jul;23(3):249-264. Pubmedid: 27556665.
- Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, Letson DG, Zager JS, Gonzalez RJ. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015 Jul;112(1):103-106. Pubmedid: 26179670.
- Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?. Geriatr Oncol. 2014 Jan;5(1):40-48. Pubmedid: 24484717. Pmcid: PMC4527303.
- Helm J, Centeno B, Coppola D, Druta M, Park J, Chen D, Hodul P, Kvols LK, Yeatman T, Carey L, Karl R, Malafa M. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008 Oct;15(4):288-294. Pubmedid: 18813196.
- Jacobsen PB, Shibata D, Siegel EM, Druta M, Lee JH, Marshburn J, Davenport L, Cruse H, Levine R, Gondi A, Brown R, Malafa M. Measuring quality of care in the treatment of colorectal cancer: the moffitt quality practice initiative. J Oncol Pract. 2007 Mar;3(2):60-65. Pubmedid: 20859375. Pmcid: PMC2793747.
